Q3 2025 Zydus Lifesciences Ltd Earnings Call Transcript
Key Points
- Zydus Lifesciences Ltd (BOM:532321) reported a strong financial performance with consolidated revenues of INR 52.7 billion, up 17% year-on-year.
- The company's EBITDA for the quarter was INR 13.9 billion, reflecting a growth of 26% year-on-year, with an improved EBITDA margin of 26.3%.
- The US Formulations business showed significant growth, accounting for 47% of consolidated revenues, with a 31% year-on-year increase.
- The Consumer Wellness business registered double-digit growth, driven by robust volume growth despite a muted demand scenario.
- Zydus Lifesciences Ltd (BOM:532321) has a strong innovation pipeline, with FDA approval for a Phase IIb clinical trial of Usnoflast for ALS and ongoing developments in biosimilars and novel biologics.
- The US business faced challenges with competition in Asacol HD, impacting sequential growth.
- There were nonrecurring expenses impacting the quarter's financials, including marketing and legal fees, and GST loss on inventory destruction.
- The gross margin declined sequentially due to changes in business and product mix, including the absence of Revlimid sales.
- The company faces potential future competition in the Asacol HD market once CGT exclusivity ends.
- There is uncertainty regarding the commercialization and revenue potential of certain specialty products, such as CUTX-101, due to the complexities of rare disease markets.
Good evening, ladies and gentlemen. Welcome to our post results teleconference for the quarter ended December 31, 2024. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Head of Investor Relations; and Mr. Alok Garg from the Managing Director's office.
Let me now give you a broad overview of the developments during the quarter. We are happy with another quarter of strong financial performance and remain on track to sustain the growth momentum going ahead. Our US.
Formulations business continued its upward revenue trajectory with a high year-on-year growth driven by volume expansion in base business as well as new products launched over the last 12 months. Our India Formulations business grew faster than the market with a secondary sales growth of 8% year-on-year, the source being IQVIA.
The Chronic segment outpaced the market growth driving the overall performance of the business. The Consumer Wellness business registered double-digit
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
